Compare HGV & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HGV | ABCL |
|---|---|---|
| Founded | 1992 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.5B |
| IPO Year | 2017 | 2020 |
| Metric | HGV | ABCL |
|---|---|---|
| Price | $41.98 | $11.47 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $52.13 | $8.40 |
| AVG Volume (30 Days) | 976.7K | ★ 9.1M |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 97.78 | 10.91 |
| EPS | ★ 0.95 | N/A |
| Revenue | ★ $5,047,000,000.00 | $75,128,000.00 |
| Revenue This Year | $25.30 | N/A |
| Revenue Next Year | $1.98 | $21.85 |
| P/E Ratio | $44.39 | ★ N/A |
| Revenue Growth | 1.33 | ★ 160.56 |
| 52 Week Low | $36.79 | $2.75 |
| 52 Week High | $55.40 | $12.58 |
| Indicator | HGV | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 36.77 | 62.27 |
| Support Level | $37.46 | $3.39 |
| Resistance Level | $43.21 | $12.58 |
| Average True Range (ATR) | 1.36 | 0.74 |
| MACD | -0.14 | -0.15 |
| Stochastic Oscillator | 16.35 | 50.77 |
Hilton Grand Vacations Inc is a timeshare company engaged in developing, marketing, selling, managing, and operating timeshare resorts and timeshare plans under the Hilton Grand Vacations brand. The company operates in two segments: Real estate sales and financing, and Resort operations and club management. The Real estate sales and financing segment generates revenue from VOI sales and consumer financing, including interest income from loans to members. The Resort operations and club management segment generates revenue from resort management services, club membership fees, and rental of available inventory. The majority of the company's revenue is earned through the Real estate sales and financing segment.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.